Thereafter, the combination treatment of FAK inhibitors with senolytic agents (drugs that selectively induce apoptosis in senescent cells) to selectively eliminate senescent cancer cells is a feasible therapeutic strategy. The gene discussed is PTK2; the disease is cancer.